AstraZeneca picks up suite of new Covid-19 antibodies, shining spotlight on Oxford-tied startup
AstraZeneca is taking another stab at developing antibodies for Covid-19.
Having partnered with Vanderbilt University researchers to develop the long-acting antibody combo now known as Evusheld, AstraZeneca this time is betting on newly-launched RQ Biotechnology, a UK-based outfit with roots at the University of Oxford and medical research charity LifeArc.
The pharma giant swooped in with a $157 million deal — plus royalties — to acquire worldwide licenses to a suite of early-stage antibodies targeting SARS-CoV-2.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.